P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY

Detalles Bibliográficos
Autores principales: Schjesvold, F, Ludwig, H, Delimpasi, S, Robak, P, Mateos, M, Sandberg, A, Thuresson, M, Norin, S, Richardson, P, Sonneveld, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171472/
http://dx.doi.org/10.1097/01.HS9.0000936280.49189.84
_version_ 1785039423865356288
author Schjesvold, F
Ludwig, H
Delimpasi, S
Robak, P
Mateos, M
Sandberg, A
Thuresson, M
Norin, S
Richardson, P
Sonneveld, P
author_facet Schjesvold, F
Ludwig, H
Delimpasi, S
Robak, P
Mateos, M
Sandberg, A
Thuresson, M
Norin, S
Richardson, P
Sonneveld, P
author_sort Schjesvold, F
collection PubMed
description
format Online
Article
Text
id pubmed-10171472
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101714722023-05-11 P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY Schjesvold, F Ludwig, H Delimpasi, S Robak, P Mateos, M Sandberg, A Thuresson, M Norin, S Richardson, P Sonneveld, P Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171472/ http://dx.doi.org/10.1097/01.HS9.0000936280.49189.84 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Poster
Schjesvold, F
Ludwig, H
Delimpasi, S
Robak, P
Mateos, M
Sandberg, A
Thuresson, M
Norin, S
Richardson, P
Sonneveld, P
P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
title P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
title_full P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
title_fullStr P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
title_full_unstemmed P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
title_short P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
title_sort p38 patient-reported outcomes (pro) in relapsed/refractory multiple myeloma (rrmm) treated with melflufen and dexamethasone (dex) or pomalidomide (pom) and dex: analyses from the phase 3 ocean study
topic Poster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171472/
http://dx.doi.org/10.1097/01.HS9.0000936280.49189.84
work_keys_str_mv AT schjesvoldf p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT ludwigh p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT delimpasis p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT robakp p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT mateosm p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT sandberga p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT thuressonm p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT norins p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT richardsonp p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy
AT sonneveldp p38patientreportedoutcomesproinrelapsedrefractorymultiplemyelomarrmmtreatedwithmelflufenanddexamethasonedexorpomalidomidepomanddexanalysesfromthephase3oceanstudy

Ejemplares similares